Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: Lancet Diabetes Endocrinol. 2023 Mar 31;11(5):345–361. doi: 10.1016/S2213-8587(23)00038-4

Figure 4.

Figure 4.

Management of patients with metastatic SDHD-related PPGLs

TKI, tyrosine kinase inhibitors

* In patients in whom CVD is not tolerated, not wished by the patient or if there are contraindications to CVD, tyrosine kinase inhibitors (sunitinib) or temozolomide can be used as alternative agents, carefully evaluating their adverse effects.